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Background: Testing for 25-hydroxyvitamin D [25(OH)D] has increased dramatically in recent years. The present
report compares overall utilization and results for 25(OH)D orders at two academic medical centers - one in New
York and one in Iowa – in order to characterize the vitamin D status of our inpatient and outpatient populations.
Results are also compared to those from a national reference laboratory to determine whether patterns at these
two institutions reflect those observed nationally.
Methods: Retrospective data queries of 25(OH)D orders and results were conducted using the laboratory
information systems at Weill Cornell Medical College / New York Presbyterian Hospital (WCMC), University of Iowa
Hospitals and Clinics (UIHC), and ARUP Laboratories (ARUP). Chart review was conducted for cases with very high or
low serum 25(OH)D levels in the WCMC and UIHC datasets.
Results: The majority of tests were ordered on females and outpatients. Average serum 25(OH)D levels were higher
in female versus male patients across most ages in the WCMC, UIHC, and ARUP datasets. As expected, average
serum 25(OH)D levels were higher in outpatients than inpatients. Serum 25(OH)D levels showed seasonal
periodicity, with average levels higher in summer than winter and correlating to regional UV index. Area plots
demonstrated a peak of increased 25(OH)D insufficiency / deficiency in adolescent females, although overall worse
25(OH)D status was found in male versus female patients in the WCMC, UIHC, and ARUP datasets. Surprisingly,
improved 25(OH)D status was observed in patients starting near age 50. Finally, chart review of WCMC and UIHC
datasets revealed over-supplementation (especially of ≥ 50,000 IU weekly doses) in the rare cases of very high 25
(OH)D levels. General nutritional deficiency and/or severe illness was found in most cases of severe 25(OH)D
deficiency.
Conclusions: 25(OH)D status of patients seen by healthcare providers varies according to age, gender, season, and
patient location. Improved 25(OH)D status was observed later in life, a finding that may reflect the previously
described increased use of vitamin D-containing supplements in such populations. Severe vitamin D deficiency is
much more common than vitamin D toxicity.
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Vitamin D is a fat-soluble vitamin important for calcium
absorption and bone health. Vitamin D also plays an im-
portant role in a variety of other functions, including
muscle strength, cellular proliferation, differentiation, and
immunomodulation to name a few (see [1] for review), and
deficiency may be associated with a variety of clinical con-
ditions and disease states [2]. Vitamin D2 (ergocalciferol) is
obtained exclusively from dietary sources, whereas vitamin
D3 (cholecalciferol) is obtained from dietary sources as well
as the conversion of endogenous 7-dehydrocholesterol by
UV-B exposure to the skin. Vitamin D2 and vitamin D3 are
hydroxylated to 25-hydroxyvitamin D2 (25(OH)D2) and
25-hydroxyvitamin D3 (25(OH)D3) respectively [collect-
ively referred to as 25(OH)D; calcidiol] in the liver. 25
(OH)D is then hydroxylated to the biologically active hor-
mone 1,25-dihydroxyvitamin D (1,25(OH)2D; calcitriol) in
the kidney and to some extent in peripheral tissues. 25
(OH)D, while an inactive precursor, is the best measure-
ment of vitamin D nutritional status (versus 1,25(OH)2D
or vitamin D itself) due to its longer half-life, less day to
day variation, and ease of measurement in the clinically
relevant concentration range [3].
Growing interest in vitamin D has led to a dramatic
increase in 25(OH)D testing in recent years [4]. This
surge in 25(OH)D orders has been a challenge for clin-
ical laboratories deciding whether to handle this testing
in-house or as send-outs to commercial reference la-
boratories. Multiple vendors now offer assays for 25
(OH)D testing, which include immunochemical, chro-
matographic, and mass spectrometric platforms [5,6].
Numerous studies, however, have demonstrated variabil-
ity of 25(OH)D results across assays [7-10]. Unfortu-
nately, variability between assays can impact studies that
examine the prevalence of vitamin D deficiency in popu-
lations, as well as clinical decisions for an individual
patient [11,12].
There is actually little consensus on reference intervals
used to determine what are optimal, sufficient, insuffi-
cient, deficient, and/or toxic levels of 25(OH)D [13]. For
example, the Institute of Medicine (IOM) has recently
defined four categories of 25(OH)D status: risk of deficiency
(<30 nmol/L; <12 ng/mL), risk of inadequacy (30–
49 nmol/L; 12–19 ng/mL), sufficiency (50–125 nmol/L;
20–50 ng/mL); and above recommended levels (>125 nmol/
L; >50 ng/mL) [14]. Data from the National Health and
Nutrition Examination Survey (NHANES) was originally
analyzed to assess the vitamin D status of the United States
population [15], and has more recently been reviewed with
these categories in mind [14]. The Endocrine Society’s 2011
clinical practice guidelines, however, describe vitamin D
deficiency as 25(OH)D of < 50 nmol/L (<20 ng/mL)
and insufficiency as 52.5-72.5 nmol/L (21–29 ng/mL)
[16]. Reference intervals may also vary based on assaypackage inserts, population-specific studies, and/or refer-
ence laboratory [13].
In the present report, we compare the ordering and re-
sult patterns of 25(OH)D testing at two large academic
medical centers: one in New York City (WCMC) and
one in Iowa City (UIHC). We subsequently compare 25
(OH)D results, as well as the distribution of results into
reference intervals by age, to those observed at a na-
tional reference laboratory (ARUP). Finally, chart review
was performed for cases of vitamin D toxicity and defi-




This report presents data from three separate retrospect-
ive reviews of 25(OH)D tests ordered by practitioners in
clinical practice. No 25(OH)D testing was ordered spe-
cifically for this report. Patients for whom 25(OH)D
tests were ordered represent a mixture of healthy and ill
individuals, and no screening was done to include and/
or exclude patients based on patient medical history in
the WCMC, UIHC, and ARUP datasets. Data were not
adjusted for survival, population trends, or relative prob-
ability of visiting a healthcare provider.
WCMC study
Two different 25(OH)D assays were available for order-
ing by clinicians in the inpatient and outpatient electronic
health systems during the period of time investigated
(October 2010 through May 2012). These were 25(OH)D
by DiaSorin immunoassay (sent to ARUP Laboratories,
Salt Lake City, UT) and 25(OH)D by LC-MS/MS (sent to
Quest Diagnostics, Teterboro, NJ). Using a protocol ap-
proved by the Weill Cornell Medical College Institutional
Review Board (WCMC IRB), the WCMC Laboratory
Information System (LIS) (Millennium, Cerner Corpor-
ation, North Kansas City, MO) was queried for all vitamin
D-related tests sent out over this 20 month interval. His-
torical ordering data (2008–2010) were reviewed to deter-
mine trends in frequency. In accordance with the WCMC
IRB protocol, chart review was then conducted to deter-
mine causes of vitamin D toxicity (100 ng/mL or greater
based on elevated 25(OH)D immunoassay results) or ex-
treme deficiency [based on both 25(OH)D2 and 25(OH)
D3 results < 4 ng/mL on 25(OH)D assays by LC-MS/MS].
UIHC study
Using a protocol approved by the University of Iowa
Institutional Review Board Biomedical (01) subcommittee
(UI IRB), the UIHC electronic health system (EpicCare,
Epic Systems Corporation, Verona, WI) was queried for
all 25(OH)D tests ordered from January 2000 through
October 2012. Several distinct 25(OH)D assays were
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taneously. From January 2000 to mid-July 2005, the
Nichols ADVANTAGEW 25-OH Vitamin D immunoassay
was performed in-house. From late-July 2005 to January
2012 specimens were sent to ARUP Laboratories (DiaSorin
immunoassay). An in-house assay, Abbott Architect 25-
OH Vitamin D (Abbott Laboratories, Abbott Park, IL) was
used from mid-January 2012 to mid-October 2012. Start-
ing in mid-October 2012, the laboratory moved to the
Roche Elecsys Vitamin D assay (Roche Diagnostics, Basel,
Switzerland) on the in-house Modular E platform. Since
only a partial month of data was available for October
2012, the October 2012 data were excluded from this re-
port. In accordance with the UI IRB protocol, chart review
was performed on all patients with 25(OH)D immunoassay
results of 100 ng/mL or greater, or less than 5 ng/mL. That
chart review was directed at medical history and potential
reasons for having elevated or severely deficient 25(OH)D
serum concentrations.
ARUP study
Using a protocol approved by the University of Utah
Institutional Review Board, a de-identified list of im-
munoassay results for 25(OH)D (DiaSorin immunoassay)
was obtained from the ARUP LIS. Exclusion criteria were
any specimens potentially received from WCMC or UIHC
to prevent duplication of results.
UV index
UV index information is available in the public domain
from the Climate Prediction Center, National Weather
Service/National Oceanic and Atmospheric Administra-
tion website [17]. UV index is defined by the National
Weather Service as “forecast of the amount of skin dam-
aging UV radiation expected to reach the earth’s surface at
the time when the sun is highest in the sky (solar noon)”
[18]. The daily “Issued UV Index” is used throughout this
paper and incorporates cloud information (as opposed to
“clear sky UV index”). Issued UV index was used from
the weather station at the John F. Kennedy International
Airport (~ 40.64°N latitude) in New York (near WCMC~
40.77°N latitude) and the weather station at the Des
Moines International Airport (~ 41.53°N latitude) in Iowa
(near UIHC ~41.66°N latitude).
Limit of quantitation and exclusions
Assays for 25(OH)D have a lower limit of quantitation.
Results below this are typically reported with a “less than”
(<) symbol. For the duration of time evaluated in this
study, the following were the lower limits of quantitation
evident in results of our queries from 2000 through
2012: Nichols Advantage (< 7 ng/mL), ARUP (< 4 ng/mL
or < 7 ng/mL), Abbott (< 4 ng/mL or < 7 ng/mL), Roche
(< 5 ng/mL). Analysis of ordering patterns and frequencywas not impacted by these “less than” results and includes
all available data. Area plot analysis (see below) also in-
cludes all “less than” results, as they could be fit within the
same interval category (ex. 0–10 ng/mL). For analysis of
25(OH)D immunoassay results by sex, age, and month,
however, “less than” results were not included, as an actual
value was unknown. For WCMC, 59 results (~0.1% of
total results; 40 female, 19 male) were excluded from ana-
lysis of 25(OH)D averages due to “less than” results.
For UIHC, 378 results (~0.6% of total results; 235 female,
143 male) were excluded due to “less than” results. For
ARUP, ~0.09% of total results (64.4% female, 35.6% male)
were excluded due to “less than” results. The difference in
the relative percent of excluded results from UIHC (versus
WCMC or ARUP) is likely due to the much longer period
of data available for analysis from UIHC and corre-
sponding improvements in 25(OH)D immunoassay per-
formance and sensitivity over time. An additional 30
“results” (20 female, 10 male) were excluded from analysis
at WCMC, as text comments instead of numeric results
were retrieved from the de-identified LIS queries.
For the LC-MS/MS total 25(OH)D and fractionated 25
(OH)D2 and 25(OH)D3 result analysis from the WCMC
dataset, exclusion of values below the lower limit of
quantitation (< 4 ng/mL; n = 6,445 for 25(OH)D2 and
n = 75 for 25(OH)D3) would lead to a marked over-
estimation of average 25(OH)D2 concentrations. For these
figures, “less than” results were therefore tabulated as
“zeros” for the purpose of graphical display and average 25
(OH)D2 and 25(OH)D3 concentration by age. Area plot
analysis of LC-MS/MS data includes all “less than” results,
as they could be fit within the same interval category.
Finally, it should be noted that repeat testing on the
same patient (pseudoreplication) could not be avoided in
the WCMC, UIHC, and ARUP datasets, as patient-level
exclusion was not possible on our IRB-approved de-
identified result queries. A separate analysis of WCMC
25(OH)D ordering, however, revealed the following dis-
tribution of 25(OH)D “orders per patient” in that inter-
val of time studied (20 months): 1 order, 69.3%; 2 orders,
19.5%; 3 orders, 6.2%; 4 orders, 2.4%; 5 orders, 1.2%; 6
orders, 0.6%; 7 orders, 0.3%; 8 orders, 0.2%; 9 orders,
0.1%; ≥ 10 orders, 0.2%.
Data analysis
Microsoft Excel 2007 and SigmaPlot 11 (Systat Software,
Inc, Chicago, IL) were used to analyze and visualize data
by age, sex, order month, and patient location. Patient
age was rounded to the nearest year to facilitate binning
and comparison. Alternate (quantitative) method com-
parison between immunoassay and LC-MS/MS (includ-
ing bias, correlation coefficient, and Deming regression)
was conducted in EP Evaluator 9 (Data Innovations,
South Burlington, VT) and plotted in SigmaPlot 11.
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was used to calculate the proportion of results by age that
fall into specific reference intervals. These results were
used to generate area plots in SigmaPlot, which display
stacked, proportionate areas such that the sum at age is
equal to 100% (see corresponding legend for a descrip-
tion). Data throughout the manuscript are presented as
mean ± standard deviation (SD) unless otherwise indi-
cated. Since results demonstrated a non-normal 25(0H)D
distribution of scores, statistical significance was evaluated
using the Mann Whitney rank sum test (with alpha set at
0.05 for the threshold of significance).
Results
25(OH)D by immunoassay
In the 20 months of testing analyzed at WCMC, 57,433
clinician orders for 25(OH)D by immunoassay and 8,439
orders for 25(OH)D by LC-MS/MS were identified. As
25(OH)D results can differ by methodology, WCMC
LC-MS/MS orders were not included in initial ordering
and result analysis, but are analyzed separately and in
the chart review of deficiency cases. In the 153 months
analyzed at UIHC, 60,237 orders for 25(OH)D by im-
munoassay were identified. Total number of immuno-
assay results reviewed from WCMC, UIHC, and ARUP
are included in Table 1. Table 2 provides summary sta-
tistics by platform for 25(OH)D immunoassay testing at
UIHC.
The vast majority of tests were ordered on outpatients
(versus inpatients) at both WCMC (95.4%) and UIHC
(91.2%) (Table 1). The total number of monthly 25(OH)D
orders increased dramatically over the interval of time
studied at both WCMC (Figure 1A) and UIHC (Figure 1B).
This increase was most prominent between 2008 and
2010 at both institutions (ex. 2008 to 2009 annual growthTable 1 25(OH)D orders and immunoassay results by instituti
Patient location # Orders females # Order
WCMCa Private Ambulatory 28911 127
Hospital Outpatient Clinics 9046 335
Inpatient 1605 99
UIHC Outpatient 37684 171
Dialysisb 67 54
Emergency Department 51 22
Inpatient 2930 192
Inpatient ICUc 167 18
ARUP Unknownd 414640 1842
aA total of 749 WCMC results (437 female, 312 male) were omitted from this table d
category not included as there were only 14 females and 2 males.
bAll UIHC dialysis patients were considered outpatients for the purpose of this anal
cUIHC inpatient ICU includes data from cardiovascular ICU, medical ICU, neonatal IC
dInpatient versus outpatient status was not identifiable. Specimens received from Wrates were 115% at WCMC and 52% at UIHC). The ma-
jority of tests were ordered on female patients, with simi-
lar percentages observed across datasets (WCMC 69.8%,
UIHC 67.9%; see Table 1). The number of 25(OH)D or-
ders in female and male patients at WCMC (Figure 1C)
and UIHC (Figure 1D) are shown by patient age. At both
institutions, the predominance of orders in female (versus
male) patients begins at approximately age 20 and con-
tinues thereafter. At WCMC, the number of test orders in
both female and male patients increased steadily between
ages of approximately 20 through 70 years old before de-
creasing (Figure 1C). At UIHC, the increase in test orders
was more pronounced between the ages of approximately
40 through 60 years old before decreasing (Figure 1D). A
greater number of orders for pediatric and adolescent pa-
tients were observed at UIHC than WCMC (Figure 1C,D),
although this may also represent differing patient popula-
tions, as New York Presbyterian Hospital’s largest chil-
dren’s hospital is not on the WCMC campus (therefore,
corresponding specimens/results are not included in the
WCMC dataset).
Figure 2 shows average 25(OH)D results by age and
gender for WCMC (Figure 2A), UIHC (Figure 2B), and
ARUP (Figure 2C) datasets. Each set shows a general de-
cline in average 25(OH)D level in adolescence, as well as
a relative stability of average 25(OH)D level between the
ages of approximately 20 to 50 years old. In each of the
datasets, average 25(OH)D levels increased after age 50
in both men and women. It is important to note that
population sizes for pediatric and geriatric patients in
the WCMC and UIHC datasets are relatively small
(see Figure 1C,D), a factor that likely contributes to the
variability in results at very young and very old ages
(Figure 2A,B). This variability is therefore less pronounced
in the much larger ARUP dataset (Figure 2C).on, patient location, and sex
Average 25(0H)D Results ± SD (ng/mL) p value
s males Female (F) Male (M) All F vs M
66 30.5 ± 13.3 28.4 ± 12.7 29.8 ± 13.2 p < 0.001
7 27.2 ± 12.4 24.9 ± 11.3 26.6 ± 12.1 p < 0.001
9 25.8 ± 19.2 21.9 ± 12.1 24.3 ± 16.9 p < 0.001
53 30.5 ± 14.6 29.8 ± 14.3 30.2 ± 14.5 p < 0.001
26.1 ± 13.0 32.6 ± 16.3 29.0 ± 14.8 p = 0.031
28.8 ± 17.5 24.8 ± 10.5 27.6 ± 15.8 p = 0.574
3 27.3 ± 16.0 25.7 ± 18.3 26.7 ± 17.0 p < 0.001
6 22.6 ± 13.4 24.8 ± 14.0 23.8 ± 13.7 p = 0.119
08 29.4 ± 13.8 28.1 ± 13.0 29.0 ± 13.6 p < 0.001
ue to uncertain designation of inpatient versus outpatient status. WCMC ED
ysis.
U, and pediatric ICU.
CMC and UIHC were excluded from ARUP result analysis.
Table 2 25(OH)D immunoassay results by assay platform – UIHC dataset
Average 25(0H)D Results ± SD (ng/mL)
Assay Dates used # Orders females # Orders males Female (F) Male (M) All
UIHC Nichols ADVANTAGEW (in-house) Jan 2000 - Jul 2005 1689 998 27.4 ± 16.6 24.9 ± 18.0 26.5 ± 17.2
DiaSorin Immunoassay (send-out) Jul 2005 -Jan 20012 32602 15092 30.6 ± 14.7 30.0 ± 15.0 30.4 ± 14.8
Abbott Architect (in-house) Jan 2012 -Oct 2012 6608 3248 29.4 ± 14.2 27.6 ± 12.2 28.8 ± 13.6
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presented in Figure 3. While the SD of results within age
groups (by gender) is large with overlapping error bars,
statistically significant differences were found between
female and male patients at most ages. At WCMC
(Figure 3A), UIHC (Figure 3B), and ARUP (Figure 3C),
average 25(OH)D results were significantly higher in
females than males at most ages (notable exception ARUP
0–9 yr olds, Figure 3C), although this trend was more pro-
nounced at WCMC and ARUP versus UIHC.
Table 1 presents average 25(OH)D results (including
all ages) for female and male patients by location. The
only locations where average 25(OH)D results were sta-
tistically higher in men than women had relatively small
population sizes (<200 per group). At WCMC, both out-
patient populations (private ambulatory and hospital-owned
clinics) showed higher 25(OH)D results than inpatientsFigure 1 25(OH)D immunoassay - orders by institution, age, and sex.
bins) at WCMC (A) and UIHC (B). Error bars are ± SD. C,D. Total number of
WCMC (C; 20 months analyzed) and UIHC (D; 153 months analyzed). Datafor both women and men (p < 0.001). Both female and
male 25(OH)D levels were significantly lower in patients
at the hospital-owned clinics versus private ambulatory
clinics (p < 0.001), a factor that may be related to different
patient populations served and/or ordering practices at
these two categories of clinics. At UIHC, 25(OH)D results
were also higher in outpatients than inpatients for both
genders (p < 0.001). 25(OH)D results were significantly
lower in female ICU inpatients than female non-ICU in-
patients (p < 0.001), although this was not true when com-
paring male results between ICU and non-ICU inpatients
(p = 0.648).
As it is known that sunlight (specifically UV-B) exposure
promotes peripheral conversion of 7-dehydrocholesterol to
previtamin D, we analyzed average 25(OH)D results for
males and female patients by order month (Figure 4A,B)
and compared this to reported regional UV IndexA, B. Average number of 25(OH)D orders per month (in six month
orders by patient age and sex (female = red lines; male = blue lines) at
are binned to 1 yr age intervals.
Figure 2 25(OH)D immunoassay – average concentration by
age and sex – results for all ages. Average 25(OH)D results at
WCMC (A), UIHC (B), and ARUP (C) by age and sex (female = red
lines; male = blue lines). Variability at young and old ages (particularly
A and B) may be due to comparatively small n-values
(see Figure 1C,D).
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Figure 4C,D) recorded at monitoring locations nearest to
the respective medical centers. As expected, 25(OH)D re-
sults were higher in summer than winter months in both
male and female patients with patterns following the sea-
sonal trends as evident in UV Index periodicity.
To view the distribution of all patient results within
specific reference intervals, proportional stacked area
plots were generated for WCMC (Figure 5C,D), UIHC
(Figure 5E,F), and ARUP (Figure 5G,H) and divided into
female patients (left column) and male patients (rightcolumn). The reference intervals for ARUP (instead of
IOM) were chosen as a starting point for area plot gen-
eration, since the majority of specimens in this report
were actually tested at ARUP. The < 20 ng/mL interval,
however, was subdivided into two separate intervals
(0–10 ng/mL and 11–19 ng/mL) to improve our ability
to view deficiency in these graphs. Since cases of toxicity
were rare, data from the >150 ng/mL “possible toxicity”
interval used by ARUP were merged into the >80 ng/mL
interval as they were too small to be visible when plotted
on the graphs. Even the >80 ng/mL interval is diffi-
cult to visualize in Figure 5 (blue shading; not always
present at a given age). A color coded legend of the
intervals displayed is indicated in Figure 5A and ap-
plies to all other area plots (Figure 5C-H). A descrip-
tion of area plot generation is also provided in the
Methods section and is illustrated in Figure 5B (and
figure legend) to assist the reader.
A peak of sub-optimal 25(OH)D status is again evident
in female adolescents (see Figure 5G ARUP data), although
in general 25(OH)D status is lower in male patients in the
WCMC, UIHC, and ARUP datasets (as suggested by upper
border of magenta interval, Figure 5C-H). A relative stabil-
ity of 25(OH)D status is again evident between the ages of
approximately 20–50 years old in WCMC (Figure 5C,D),
UIHC (Figure 5E,F), and ARUP (Figure 5G,H) datasets. An
increase in optimal 25(OH)D levels (yellow shading) was
observed after approximately age 50 in the WCMC, UIHC,
and ARUP datasets.
25(OH)D by LC-MS/MS
The WCMC inpatient and outpatient electronic health
systems permitted clinicians to electronically order 25
(OH)D by immunoassay and/or 25(OH)D by LC-MS/MS,
as described in the Methods section. Given the availability
of both assays, in our dataset review we identified 443
cases in which both immunoassay and LC-MS/MS were
ordered by clinicians on the same specimen. Analysis of
these paired results (Figure 6A), revealed a correlation
coefficient (R) of 0.85 and an overall bias (LC-MS/MS to
immunoassay) of 3.5 ng/ml (11.5%). As the LC-MS/MS
assays were reported with three components - total 25
(OH)D and fractionated 25(OH)D2 and 25(OH)D3 – it
was possible to plot 25(OH)D2 versus 25(OH)D3 for speci-
mens in which LC-MS/MS was ordered (n = 8,439). This
analysis (Figure 6B) revealed that in the majority of speci-
mens (76.4%; n = 6,445; overlapping red dots), 25(OH)D2
was not quantifiable while 25(OH)D3 was quantifiable. In
a small minority of specimens (0.89%; n = 75; green dots),
25(OH)D2 was quantifiable while 25(OH)D3 was not
quantifiable. In a smaller minority of specimens (0.20%;
n = 17; overlapping black dot), neither were quantifiable.
In the remaining specimens (22.5%; n = 1,902; blue dots),
both 25(OH)D2 and 25(OH)D3 were quantifiable.
Figure 3 25(OH)D immunoassay – average concentration by age and sex – results by decade of life. A,B. Average 25(OH)D results at
WCMC (A), UIHC (B), and ARUP (C) by age (in 10 year bins) and sex [female = red circles; male = blue circles]. Error bars are ± SD. * p < 0.05.
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(OH)D2 and 25(OH)D3 by age for female (Figure 6C)
and male (Figure 6D) patients. While there is significant
scatter in the data due to the relatively small number of
specimens for patients at each age (Figure 6E, females;
Figure 6F, males; 1 yr bins), the overall trend in 25(OH)
D3 results is similar to the 25(OH)D immunoassay re-
sults observed in Figure 2A-C, supporting a hypothesis
that the increase in optimal 25(OH)D concentrations
observed in later adulthood (see Figures 2, 3, and 5) are
primarily due to increased concentrations of serum 25Figure 4 25(OH)D immunoassay – average concentration by order mo
(A) and UIHC (B) by sex [female = red circles; male = blue circles] and orde
City, NY (C) and Des Moines, IA (D) (see Methods).(OH)D3. Reference range area plots were also generated
for total 25(OH)D by LC-MS/MS at WCMC (Figure 6G,
females; Figure 6H, males). While increased scatter is
again noted due to the relatively small number of speci-
mens, the overall pattern is relatively consistent with that
observed in 25(OH)D immunoassay results (Figure 5).
Chart review – elevated 25(OH)D
Chart review was performed on all UIHC and WCMC
patients who had 25(OH)D levels of 100 ng/mL or
greater (see Table 3). At UIHC, over the nearly 13 yearsnth with regional UV index. A,B. Average 25(OH)D results at WCMC
r month. Error bars are ± SD. C,D. Daily issued UV Index for New York
Figure 5 25(OH)D immunoassay – results by reference intervals. A. Figure legend showing the colors representing reference intervals used
in B through H. An asterisk (*) is indicated next to the >80 ng/mL intervals (blue) in A and B, as this interval often contains too few specimens
to be easily visible at this magnification (also evident in C through H). B. Presentation of population data as area plots. For any given group
(for example, WCMC female patients age 45 shown here) the percent of patients that fall into specific reference intervals can be represented as a
pie chart (B, left example). To the right of the pie chart is a “proportional stacked plot” (B, middle) that shows the same data, but now stacked by
color-coded reference intervals (low to high) such that the sum of all areas equals 100%. These data can also be presented as a narrower stacked
color-coded “single line” (B, right). Graphing “single line” area plots for all ages (aligned by increasing age) produce the area plots shown below.
C-H. Area plots show the reference interval distributions for all ages (0–100 yrs; 1 yr bins) in females (C, E, G) and males (D, F, H) at WCMC
(C,D), UIHC (E,F) and ARUP (G,H). The UIHC dataset does not include any males greater than 97 years old (F). Overlying reference lines (dotted)
have been added at 20% intervals to all area plots (C-H) to facilitate comparison across graphs.
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http://www.biomedcentral.com/1472-6823/13/52of results reviewed, only 27 patients (~0.05%) had 25
(OH)D levels greater than 150 ng/mL. An additional 82
patients (~0.14%) had 25(OH)D levels between 100
and 150 ng/mL. The highest 25(OH)D level at UIHC
(851 ng/mL) was seen in a patient with X-linked hypopho-
sphatemia. There were only 3 additional patients with a
25(OH)D level of 300 ng/mL or higher. For patients with
25(OH)D of 126 ng/mL or greater in the UIHC dataset,
27.5% were observed in patients taking a 50,000 unit vita-
min D2 prescription more often than once weekly. An
additional 31.4% were attributed to patients taking very
high doses of over-the-counter vitamin D supplementsoutside of physician recommendations. Interestingly, only
3 patients out of the 109 total who had 25(OH)D of
100 ng/mL or greater had hypercalcemia (defined as above
upper limit of age-specific reference range for total and/or
ionized calcium). Only one of these patients was hospital-
ized for management of hypercalcemia - a 70 year old fe-
male with dementia and acute renal failure in addition to
hypercalcemia with a 25(OH)D level of 194 ng/mL. There
were no cases of vitamin D-based rodenticide poisoning
in the UIHC dataset.
In the UIHC review there were only 3 pediatric patients
(17 years or younger) who had 25(OH)D of 126 ng/mL or
Figure 6 25(OH)D by LC-MS/MS - WCMC dataset. A. 25(OH)D immunoassay results versus LC-MS/MS total 25(OH)D results in cases where both
tests were ordered by clinicians on the same specimen. Deming regression (red dashed line) shows a slope of 0.958 and a Y-intercept of 4.7 ng/ml. B.
Corresponding fractionated 25(OH)D2 and 25(OH)D3 results from specimens ordered for 25(OH)D testing by LC-MS/MS from WCMC. See Results
section for n-values. Many data points are obscured due to overlapping position. Both X- and Y-axes are cropped at 100 ng/ml to improve visibility.
Red dots (many overlapping) = unquantifiable 25(OH)D2, quantifiable 25(OH)D3. Green dots = quantifiable 25(OH)D2, unquantifiable 25(OH)D3. Black dot
(overlapping) = unquantifiable 25(OH)D2 and unquantifiable 25(OH)D3. Blue dots = quantifiable 25(OH)D2 and quantifiable 25(OH)D3. C,D. Average 25
(OH)D2 (gray line) and average 25(OH)D3 (magenta line) results age and sex (C, females; D, males) at WCMC. Variability may be due to comparatively
small n-values as shown by specimen counts in each 1 yr bin (E, females; F, males). G,H. Area plots show the reference interval distributions for all ages
(1–90 yrs; 1 yr bins) in females (G) and males (H) at WCMC. Figure legend (color) for area plots is identical to Figure 5A.
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http://www.biomedcentral.com/1472-6823/13/52greater. The pediatric patients were 23 months old
(182 ng/mL), 4 years old (292 ng/mL) and 17 years old
(146 ng/mL). The elevated 25(OH)D in the first two pa-
tients were attributed to high prescription vitamin D doses
which were adjusted once the elevated 25(OH)D serum
concentration was known.At WCMC, over the 20 months of results reviewed,
only 15 patients (~0.03%) had 25(OH)D levels > 150 ng/mL,
with an additional 35 (~0.06%) having a measurement be-
tween 100 and 150 ng/mL. Vitamin D supplementation
was specifically mentioned in 29 of these 50 cases, with
actual and/or estimated doses documented in 24 of these






















UIHCb > 200 11 43.9 ± 18.3 5 (45.4%) 1 (9.1%) 4 (36.3%) 4 (36.3%) 0
151 – 200 16 58.0 ± 19.6 10 (62.5%) 2 (12.5%) 4 (25.0%) 6 (37.5%) 2 (12.5%)
126 – 150 24 53.1 ± 17.4 18 (75.0%) 0 6 (25.0%) 6 (25.0%) 1 (4.2%)
100 – 125 58 49.5 ± 20.0 38 (65.5%) 2 (3.4%) 6 (10.3%) 4 (6.9%) 0
WCMC > 200 5 58.8 ± 21.5 4 (80.0%) 0 1 (20%) 3 (60%) 4 (80%)
151 – 200 10 46.0 ± 14.9 7 (70.0%) 0 3 (30%) 4 (40%)c 0
126 – 150 6 58.8 ± 12.1 6 (100.0%) 1 (16.7%) 1 (16.7%) 0d 0
100 – 125 29 57.0 ± 16.8 25 (86.2%) 0 4 (13.8%) 10 (34.5%) 0
aAge < 18 years old.
bIncluding repeat measurements on patients, there were 16, 22, 27, and 75 total measurements in the > 100 ng/mL, 151–200 ng/mL, 1260–150 ng/mL,
and 100–125 ng/mL categories, respectively.
cOne additional patient received monthly 50,000 IU Vitamin D doses, not listed as given by prescription.
dOne additional patient received “Vitamin B12 and D” injections (no doses listed), not listed as given by provider.
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http://www.biomedcentral.com/1472-6823/13/52cases. In 10 cases “vitamin D deficiency” was mentioned
in prior clinic notes, suggesting that the elevated 25(OH)
D result was in response to therapy. Four of the 50
WCMC patients with 25(OH)D levels of 100 ng/mL or
greater had hypercalcemia, and each of these four had 25
(OH)D levels > 150 ng/mL. As with UIHC, there were no
cases of vitamin D-based rodenticide poisoning in the
WCMC dataset.
The highest 25(OH)D level at WCMC (409 ng/mL)
was in a patient hospitalized for symptoms associated with
severe hypercalcemia. This patient subsequently disclosed
to clinicians that she had been consuming massive amounts
of over-the counter vitamin D and calcium-containing
supplements. Only one other patient had a 25(OH)D level
of 300 ng/mL or greater. That patient (an elderly male
with dementia, chronic renal insufficiency, and recurrent
Staghorn calculi) had been diagnosed one year earlier by
his clinician with “vitamin D deficiency” due a 25(OH)D
level of 24 ng/mL. It was unclear what the prescribed and/
or consumed amount of vitamin D supplementation was,
nor was it evident whether the history of renal calculi pre-
dated the vitamin D supplementation. At WCMC, there
was only one pediatric patient with a 25(OH)D value of
100 ng/mL or greater, a 4 month old diagnosed with
osteogenesis imperfecta (25(OH)D result of 130 ng/mL)
receiving vitamin D supplementation.
In 12 of the 50 WCMC patients identified with 25(OH)D
levels of 100 ng/mL or greater, bone disease (osteoporosis,
osteopenia, scoliosis, and/or fracture) was documented by
the clinicians. Four of the 50 WCMC cases showed vitamin
D supplementation in the context of Crohn’s disease, ul-
cerative colitis, and/or inflammatory bowel disease. Five of
the 50 WCMC cases showed vitamin D supplementation in
the context of multiple sclerosis.Chart review – decreased 25(OH)D
Chart review was also conducted to investigate possible
causes for severe 25(OH)D deficiency in UIHC and
WCMC patients (Table 4). For the UIHC dataset, chart
review was conducted for cases of “severe vitamin D defi-
ciency” with total 25(OH)D < 5 ng/mL. This occurred in
185 patients over a 13 year period. A likely primary cause
of severe vitamin D deficiency could be ascertained from
chart review in 134 out of 185 patients (72.4%). The most
common suspected causes were severe dysfunction of
the liver and/or biliary tract (n = 26), lipid malabsorption
syndrome (n = 25, examples included cystic fibrosis, abeta-
lipoproteinemia, celiac disease, and inflammatory bowel
disease), and morbid obesity/post-gastric bypass surgery
(n = 23). Only 54 of 185 (29.2%) patients had a total cal-
cium serum concentration below age-appropriate reference
range at time of 25(OH)D measurement. Forty patients
were not taking vitamin D supplements prior to 25(OH)D
measurements.
For the WCMC dataset, chart review was conducted
for cases of “severe deficiency” where 25(OH)D2 and 25
(OH)D3 results by LC-MS/MS were both <4 ng/mL. Of
8,439 orders for 25(OH)D by LC-MS/MS, 14 distinct pa-
tients (0.17%) met this criteria. One of these 14 patients,
however, had a separate 25(OH)D result by immuno-
assay reported on the same specimen with discordant re-
sults of 21 ng/mL. As no clinical history was available
for this patient, it was excluded from further analysis
due to possible mix-up and/or analytical error. Of the
remaining 13 patients (see Table 4), three had a history
of prior bariatric surgery (one with complications), one
presented for a pre-operative evaluation for bariatric sur-
gery, three had renal failure (two were status post renal
transplant while the other had nephrotic syndrome), one
Table 4 Clinical characteristics for patients with
extremely low 25(OH)D resultsa
Number of
patients
Clinical characteristics UIHC WCMC
Decreased production or intake of vitamin D
Severe malnutrition 6 -b
Skin damage (e.g., burns) 0 0
Malabsorption of vitamin D or deficient 25-hydroxylation
Liver failure and/or biliary tract dysfunction 26 1
Other disorder with lipid malabsorption 25 0
Increased loss of 25(OH)D
Nephrotic syndrome 5 1
Renal failure 23 2
Increased catabolism or 1α-hydroxylation of 25(OH)D
Liver-enzyme inducing medications 7 0
Hyperthyroidism 0 0
Granulomatous disease 4 0
Other conditions possibly linked to 25(OH)D deficiency
Morbid obesity and/or status post bariatric surgery 23 4
Systemic lupus erythematosus without lupus
nephritis
8 0
Systemic lupus erythematosus with lupus nephritis 4 0
Unknown/Other 51 3
Perinatally acquired HIV; now in adolescence or
adulthood
0 2
Primary hyperparathyroidism 3 0
aThresholds for Deficiency Chart review were: UIHC, 25(OH)D immunoassay
results of <5 ng/mL; WCMC, 25(OH)D LC-MS/MS results where both D2 and D3
were <4 ng/mL.
bAt WCMC, six of the cases noted signs of malnourishment and/or
documented poor appetite. These cases are categorized, however, under the
primary causative Clinical Characteristics to eliminate duplication.
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did not have a clear documented cause. It should be
noted that in six of the cases, signs of malnourishment
and/or poor appetite were documented by the clinicians.
Interestingly, two patients had a history of perinatally ac-
quired HIV but were now in late adolescence or adult-
hood, although it should be emphasized that poor dietary
habits were noted for one of these two cases as well. Chart
review revealed documentation of subsequent vitamin D
supplementation in 8 of the 13 cases reviewed.
Discussion
A number of studies have examined vitamin D status in
large populations. For example, comprehensive analyses of
NHANES data have previously been conducted [14,15,19].
A few of the findings of NHANES differ, however, from
observations described here for the WCMC, UIHC, and
ARUP clinical datasets. For example, the NHANES studies
indicated that 25(OH)D concentrations are, in general,higher in males than females [15,19]. A second obser-
vation of the published NHANES data is that children
tended to have higher 25(OH)D concentrations than
adults [15]. While we observed a general pattern of
more optimal 25(OH)D status in childhood in all datasets
analyzed, an improvement in 25(OH)D status later in adult-
hood was observed at WCMC, UIHC, and ARUP, demon-
strating that 25(OH)D status changes throughout life.
For the WCMC dataset, we were able to demonstrate
this pattern using both immunoassay and LC-MS/MS
25(OH)D results.
It is likely that consumption of vitamin D fortified
foods, as well as UV exposure during childhood [20,21]
support 25(OH)D status during youth. Studies of the
Canadian Health Measures Surveys data have been able
to demonstrate that vitamin D supplementation contrib-
utes to improved 25(OH)D status [22], as was frequent
milk consumption and white racial background among
other factors [23]. It should be noted that American fe-
male adolescents report consuming less milk than male
adolescents [24], and in general, girls (during childhood
and adolescence) have been reported to spend less time
outdoors than boys [21]. These factors may contribute
to the patterns observed for female adolescents through-
out this report.
We suspect that increased use of vitamin D-containing
supplements (specifically vitamin D3) during later adult-
hood contributes to the improved 25(OH)D status ob-
served at those ages [25]. Elevation of 25(OH)D3 levels as
measured by LC-MS/MS (Figure 6C,D) supports this
hypothesis. Increased use of supplemental vitamin D in
women versus men is also likely to contribute to the more
optimal 25(OH)D status in women seen in our report [25].
It should be noted that another large study of approxi-
mately 158,000 individuals who had 25(OH)D testing
performed at Calgary Laboratory Services in Alberta,
Canada also found higher 25(OH)D levels in female than
male patients and improved mean 25(OH)D levels later
in adulthood (described as a nadir in early adulthood)
[26]. A population-based study in São Paulo, Brazil of
636 participants showed similar correlations regarding
age, sex, and mean 25(OH)D concentrations [27]. Other
population studies, however, have shown higher 25(OH)
D values in males than females [28]. Finally, seasonal/
UV-B dependent variation in 25(OH)D levels have been
well-characterized in numerous prior studies [29-35], as
well as a more recent excellent report analyzing 3.44
million U.S. patient samples [36].
It is tempting to speculate that differences in 25(OH)D
levels between females and males could also be due to dif-
ferences in circulating vitamin D binding protein (DBP;
also known as Gc globulin). For example, some previous
studies have found higher circulating DBP levels in women
versus men [37,38], including higher levels in pregnant
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shown a correlation between DBP levels and age, although
their population sizes [n = 100 participants, men >45 years
old and women >55 year old, ref [37]; n = 228 participants,
age ranges 18–69, ref [38]] may theoretically preclude the
ability to see any subtle trends if present. Furthermore, one
of these studies actually demonstrated lower 25(OH)D
levels in women versus men [37]. Until clinically-approved
DBP assays are commercially available and/or DBP re-
search assays are included in larger population studies, we
may not have a complete picture of whether DBP levels
vary throughout one’s lifetime. While the clinical relevance
of circulating DBP levels to vitamin D status is not fully
understood, studies have demonstrated that DBP polymor-
phisms can affect circulating 25(OH)D levels, as well as re-
sponse to vitamin D supplementation and sun exposure
[39-42]. Of particular relevance to the clinical laboratory,
new evidence demonstrates an inverse correlation between
the deviation of most vendor 25(OH)D immunoassay kits
(versus an LC-MS/MS) and DBP levels, a finding that may
explain some of the inaccuracies observed with 25(OH)D
immunoassays [9].
One limitation of the present study is that patient eth-
nicity was not available in our datasets; therefore, results
could not be subdivided by race. It is reasonable to as-
sume that WCMC and UIHC 25(OH)D datasets may
not be fully representative of national demographic pat-
terns. U.S. Census data for 2010 reports an 86.1% white
ethnicity in zip code 10065 (WCMC) and 88.8% white
ethnicity in zip code 52242 (UIHC) [43]. These percent-
ages, however, are likely much higher than the percent
of white populations observed at these facilities, which
both provide inpatient and outpatient care to patients
far beyond a single zip code. No demographic informa-
tion was available for the ARUP dataset, but it may be
more representative of the U.S. population as a whole
due to its status as a national reference laboratory. Fi-
nally, we were not able to control for any potential gen-
der differences in the relative likelihood of visiting a
healthcare provider in our patient populations.
Other limitations of the present report are the variability
inherent to including multiple immunoassay platforms in
our datasets (see Methods), as well as any potential short-
and/or long-term changes in assay performance character-
istics that can sometimes be observed in the clinical
laboratory setting. While we observed differences in aver-
age 25(OH)D results across different assay platforms
(see Table 2), it is important to note that ordering prac-
tices for 25(OH)D testing have dramatically shifted over
time. A change from prior testing primarily for clinically
suspected deficiency toward the more recent widespread
utilization of such testing in otherwise healthy individuals
likely confounds the attempt to utilize our dataset for dir-
ect assay comparisons. As our all of the testing, however,was ordered by clinicians and used in the management of
patient care, we believe that it is appropriate to include all
available data for patient averages and reference interval
distributions in the present report, while acknowledging
that some degree of bias may be introduced by including
multiple assays in such analysis.
In our chart review, most cases of 25(OH)D levels greater
than 150 ng/mL (potentially toxic) were due to vitamin D
over-supplementation (especially use of 50,000 IU prescrip-
tion vitamin D2 at weekly or greater intervals, intake of
prescribed daily vitamin D that approximated or exceed
weekly totals of >50,000 IU, and/or very heavy use of
over-the-counter supplements outside of physician recom-
mendations). Frequently, however, vitamin D intake was
not well documented. In some cases, the dose recorded in
the patient’s chart was far below what would be expected
to cause potentially toxic levels. It is unclear whether
this represented inaccurate/incomplete documentation
or hypersensitivity to vitamin D.
It should be noted that elevated 25(OH)D results were
uncommon at both UIHC and WCMC. For the UIHC
population, only 27 of 60,237 tests (~0.05%) ordered over
an approximately 13 year period had values >150 ng/mL.
Of these 27 patients, only three had hypercalcemia and
only one was hospitalized in critical condition. At WCMC,
15 of 57,433 orders for 25(OH)D by immunoassay
(~0.03%) had values > 150 ng/mL. Of these 15, only four
had hypercalcemia and only one was hospitalized (also in
critical condition). While it was clear that documentation
of over-the-counter supplementation was frequently ab-
sent or incomplete in our chart review, it is possible that
vitamin D toxicity may only been suspected when symp-
toms (and/or laboratory findings) consistent with hyper-
calcemia were observed. In this era of increased attention
to (and supplementation of) vitamin D, it would be pru-
dent to keep the possibility of vitamin D toxicity in the
differential diagnoses of patients receiving large doses of
vitamin D2 or vitamin D3.
Conclusions
In conclusion, the present report describes the order and
result patterns for 25(OH)D testing at two large academic
medical centers, and shows that these data are reflective
of results observed at a national reference laboratory. Fu-
ture studies on large populations may be necessary to fully
understand vitamin D status throughout life.
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